Guide
Electronic Batch Records (EBR): A Practical Readiness Guide
An Electronic Batch Record (EBR) system replaces the paper batch manufacturing record — the legally required document under 21 CFR 211.188 (US) and EU GMP Chapter 4 §4.20 that captures every step of producing a batch of drug product or medical device — with a validated electronic system that enforces the master batch record, captures execution data in real time, integrates with process equipment and laboratory systems, and produces an auditable, review-by-exception batch record. EBR is the highest-leverage operational upgrade in GMP manufacturing: a well-implemented EBR cuts batch release cycle time from 14-30 days to 2-5 days, eliminates the documentation deviation category that dominates paper-based DMRs, and produces the data backbone for continued process verification under FDA's 2011 process validation guidance. This guide is for QA leads, manufacturing IT, and operations directors evaluating, selecting, or implementing an EBR system in pharmaceutical, biotech, medical device, or contract manufacturing operations.
Start free trial Free trial, no credit card, onboard in days, not months.
MBR, EBR, and what each one is for
The Master Batch Record (MBR) is the controlled template — the approved set of instructions for manufacturing a specific product at a specific facility, including formula, equipment, in-process controls, sampling plan, packaging, and labelling. The Electronic Batch Record (EBR) is the execution instance of the MBR for one specific batch, populated with the actual data captured during manufacturing: who, when, what equipment, what raw material lots, what process parameters were achieved, what in-process tests passed, what deviations occurred. The EBR system enforces the MBR (operators cannot execute out of sequence, cannot enter values outside the MBR-defined limits without a deviation, cannot complete a step until the prior step is signed). The output is a legally compliant batch record that QA reviews to release the batch.
21 CFR Part 11 and EU GMP Annex 11 compliance
Any electronic system that creates, modifies, maintains, or transmits GMP records must comply with 21 CFR Part 11 (US) and EU GMP Annex 11 (EU). The two regulations are aligned but not identical. Both require: validated systems, audit trails on every GMP-relevant record showing who changed what, when, and why; secure user accounts with role-based access; electronic signatures with the components of identity verification, intent, and meaning of the signature; archive and retrieval for the record retention period (typically 7+ years post-batch expiry). Annex 11 adds explicit risk management, supplier assessment, and business continuity expectations. An EBR system that has not been formally validated against an approved validation plan is not compliant with either regulation regardless of how good the software is.
Review by exception — the operational payoff
Paper batch record review is line-by-line: a QA reviewer reads every page, verifies every signature, checks every recorded value against the spec, and flags anything questionable for investigation. The median pharmaceutical batch record review takes 8-12 hours. Review by exception is the EBR operational mode that flips this: the system pre-validates every captured value against the MBR-defined limits at the moment of capture, so values inside limits never reach a reviewer. The reviewer only handles exceptions — out-of-limit values, deviations, missing data, manual overrides — typically 5-15 exceptions per batch instead of 1,500 line items. Review time drops to 30-90 minutes per batch. This is where the EBR business case lands.
Exception management and deviation linkage
An exception in an EBR is any data point or step that did not execute within the MBR-defined parameters: a temperature excursion, a weight outside tolerance, a missed in-process test, an operator override, an unplanned line stop. Each exception must be captured at the moment of occurrence with the contextual data (what was happening, what the values were, who was on the line) and must link to the deviation system for root cause analysis, impact assessment, and CAPA if needed. The strongest EBR implementations make exception capture trivially fast (a single click + free-text) and the deviation linkage automatic, so the operator's path of least resistance is to capture rather than to ignore. Weak implementations require a separate deviation form and produce systematic under-reporting.
Integration with MES, LIMS, ERP, and process equipment
An EBR system that operates in isolation captures less than half of its potential value. The standard integration set is: MES (Manufacturing Execution System) for shop-floor scheduling and material genealogy; LIMS (Laboratory Information Management System) for in-process and release test results; ERP for material consumption, lot release, and finished goods receipt; and SCADA / DCS / standalone equipment for direct capture of process parameters (temperature, pressure, agitation, weight, time). The integration architecture (ISA-95 levels, OPC UA, REST APIs, file-based exchange) determines what's possible and how much engineering effort it takes. The most common pitfall is buying an EBR with elegant native interfaces and discovering that the existing MES/LIMS/equipment is on protocols the EBR vendor does not natively support.
Validation: CSV vs CSA, and the validation deliverables
Computer System Validation (CSV) for an EBR has historically been document-heavy: URS, FRS, FDS, IQ, OQ, PQ, traceability matrix, validation summary report, often 500-1,500 pages per EBR project. FDA's 2022 draft guidance on Computer Software Assurance (CSA) signals a shift to risk-based testing — high-risk functions get rigorous testing, low-risk functions get lighter assurance, and unscripted exploratory testing is acceptable. EU GMP Annex 11 has supported risk-based validation since 2015. The validation deliverable set for a modern EBR rollout is: validation plan; risk assessment per system function; URS-to-test traceability; IQ/OQ for the platform; PQ in the production environment with real batches; validation summary report; and the ongoing periodic review cadence.
A 120-day EBR readiness path
Days 1 to 15: scope (which products, which lines, which integrations); URS; risk assessment; vendor shortlist and demo on customer batch data. Days 16 to 40: vendor selected; system implementation kickoff; integration architecture confirmed; first MBR conversion from paper to EBR template. Days 41 to 70: platform IQ/OQ executed; first MBR template approved; integrations to LIMS/MES/ERP tested; SOPs and training material drafted. Days 71 to 100: PQ batches executed in production environment; review-by-exception workflow tuned; deviation system integration validated; operator and QA training. Days 101 to 120: go-live on first product/line; parallel paper-and-EBR for one batch; full EBR for subsequent batches; lessons learnt fed back into MBR template library for next product rollout.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
21 CFR Part 11
Part 11 makes electronic records and signatures legally defensible by requiring validation, audit trails, security, signature controls, accurate copies, and retention in line with underlying FDA recordkeeping rules.
EU Annex 11
Annex 11 defines how GMP computerized systems must be validated, controlled, and monitored to protect product quality and patient safety across the EU, with strong data integrity and lifecycle expectations.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
Is EBR required by regulation?
No. 21 CFR 211.188 requires a batch production and control record but does not mandate electronic. Paper batch records remain legal. The drivers for moving to EBR are operational (cycle time, deviation rate, data integrity) and competitive, not regulatory. That said, the data-integrity expectations under FDA, MHRA, and PIC/S guidance have hardened to the point where paper batch records create more inspection risk than they did a decade ago.
Does EBR eliminate the paper batch record?
Yes, when properly implemented and validated. The validated EBR is the legal record. Many manufacturers keep a printed PDF copy of the executed EBR as a convenience for QA review and inspection, but the electronic record is the primary record. The print is a representation, not the source of truth.
How long does an EBR implementation actually take?
First product on EBR typically lands at 4-6 months for a focused single-product, single-line scope with a vendor that ships pre-validated software. Multi-product, multi-site rollouts run 12-24 months. The biggest variable is integration scope — MES, LIMS, ERP, and equipment integrations consume 60-70% of the total project effort. Manufacturers who scope EBR-only with deferred integrations get to value faster.
Can we use the same EBR system for pharma and medical device manufacturing?
Yes, if the system supports both 21 CFR Part 211 (pharma) and 21 CFR Part 820 / QMSR (medical device) record requirements. The underlying capabilities — MBR-driven execution, review by exception, audit trail, e-signature, deviation linkage — are the same. The differences are in the record content (DHR vs BMR), the genealogy expectations, and the post-market data feeds. V5 supports both.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- 10 CFR 35 medical use readiness — NRC licensing for radiopharmaceuticals
- 21 CFR 111 Readiness: Dietary Supplement cGMP Subparts E & F
- 21 CFR 211 Drug cGMP Readiness Guide
- 21 CFR 212 PET drug cGMP readiness — FDA inspection playbook
- 21 CFR 589 BSE / Ruminant Feed Ban Readiness Guide
- 21 CFR 820 to ISO 13485 Mapping Guide (Including QMSR Harmonisation)
Spot something off? .